港股異動 | 賽生藥業大漲逾16% 機構指其逐步進入放量期

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

港股異動 | 賽生藥業大漲逾16% 機構指其逐步進入放量期

格隆匯 12-12 10:16

格隆匯12月12日丨賽生藥業(6600.HK)再度拉昇漲超16%，現報10.33港元，總市值71億港元。中金最新報吿稱，維持賽生藥業“跑贏行業”評級，2022-23年盈利預測不變，目標價11港元。公司核心品種增長穩健，持續貢獻穩定現金流。同時增量業務圍繞優勢科室拓展布局，逐步進入放量期。並且主業盈利能力總體穩定。此外，公司於12月8日公吿達佑澤(那西妥單抗)獲國家藥監局批准，用於復發難治性高危神經母細胞瘤患者治療。

賽生藥業(06600.HK)

Relevant Stocks

賽生藥業(06600.HK)

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

港股異動 | 賽生藥業大漲逾16% 機構指其逐步進入放量期

Services

About Us

Agreement Statement